STOK Stock: Price, Earnings History and SEC Filings
Stoke Therapeutics, Inc. (STOK) last traded at $26.29, down 0.23% on the latest session and up 1.1% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $-1.08 against an analyst estimate of $-0.88, a miss of 22.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
STOK earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $-1.08 | $-0.88 | -22.73% |
| Jun 2026 | Aug 3, 2026 | $-0.93 | $-0.82 | -13.41% |
| Mar 2026 | May 7, 2026 | $-0.79 | $-0.80 | +1.25% |
| Dec 2025 | Mar 16, 2026 | $-0.97 | $-0.75 | -29.33% |
STOK beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How STOK reacts to earnings
Across its last 8 earnings releases, STOK moved 7.8% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | After close | -0.23% |
| 2026-08-03 | After close | +7.14% |
| 2026-05-07 | After close | +0.30% |
| 2026-01-12 | Before open | -10.44% |
| 2025-11-04 | After close | -9.94% |
| 2025-08-12 | After close | +24.98% |
| 2025-05-13 | Before open | -7.56% |
| 2025-03-18 | Before open | -1.44% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
Latest SEC filings for STOK
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Sep 25, 2026Officer or director change
- 8-K · Aug 3, 2026Other events, Financial statements and exhibits
- 424B5 · Aug 3, 2026
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 30, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 7, 2026
Insider filing activity
STOK insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
STOK news
- Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn QuestionOct 31, 2026 · finance.yahoo.com
- Stoke (STOK) Q3 2026 Earnings Call TranscriptOct 30, 2026 · fool.com
- Stoke Therapeutics, Inc. Q3 2026 Earnings Call SummaryOct 30, 2026 · app.moby.co
- Stoke Therapeutics Q3 Earnings Call HighlightsOct 30, 2026 · marketbeat.com
- Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesOct 29, 2026 · finance.yahoo.com
- Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsightOct 27, 2026 · finance.yahoo.com
- Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesOct 22, 2026 · finance.yahoo.com
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.